Outcomes of allogeneic ocular surface stem cell transplantation.

IF 2.4
Frontiers in ophthalmology Pub Date : 2026-06-11 eCollection Date: 2026-01-01 DOI:10.3389/fopht.2026.1836045
Albert Y Cheung, Natalia Quiroz-Casian, Enrica Sarnicola, Gautam C Ramanathan, Siddharth Nath, Edward J Holland
{"title":"Outcomes of allogeneic ocular surface stem cell transplantation.","authors":"Albert Y Cheung, Natalia Quiroz-Casian, Enrica Sarnicola, Gautam C Ramanathan, Siddharth Nath, Edward J Holland","doi":"10.3389/fopht.2026.1836045","DOIUrl":null,"url":null,"abstract":"<p><p>Allogeneic ocular surface stem cell transplantation (OSST) is an established therapeutic approach for limbal stem cell deficiency, utilizing techniques such as keratolimbal allograft (KLAL), living-related conjunctival limbal allograft (lr-CLAL), allogeneic cultivated limbal epithelial transplantation (allo-CLET), and allogeneic simple limbal epithelial transplantation (allo-SLET). This review synthesizes evidence from 35 studies encompassing 1, 268 eyes with at least 24 months of follow-up to evaluate intermediate- and long-term outcomes. Overall, OSST is associated with improvement in visual acuity and restoration of ocular surface stability, although success rates vary widely by technique, ranging from 13% to 87%. Outcomes appear to be influenced by the intensity of systemic immunosuppression, with triple-agent regimens demonstrating higher rates of long-term success compared with single- or dual-agent approaches. Among techniques, lr-CLAL may offer advantages over KLAL due to lower rejection rates. Despite encouraging results, long-term data remain limited for newer approaches such as allo-CLET and allo-SLET. Careful postoperative monitoring and management of complications, including rejection, glaucoma, and microbial keratitis, remain essential to optimize outcomes.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"6 ","pages":"1836045"},"PeriodicalIF":2.4000,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13293912/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fopht.2026.1836045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Allogeneic ocular surface stem cell transplantation (OSST) is an established therapeutic approach for limbal stem cell deficiency, utilizing techniques such as keratolimbal allograft (KLAL), living-related conjunctival limbal allograft (lr-CLAL), allogeneic cultivated limbal epithelial transplantation (allo-CLET), and allogeneic simple limbal epithelial transplantation (allo-SLET). This review synthesizes evidence from 35 studies encompassing 1, 268 eyes with at least 24 months of follow-up to evaluate intermediate- and long-term outcomes. Overall, OSST is associated with improvement in visual acuity and restoration of ocular surface stability, although success rates vary widely by technique, ranging from 13% to 87%. Outcomes appear to be influenced by the intensity of systemic immunosuppression, with triple-agent regimens demonstrating higher rates of long-term success compared with single- or dual-agent approaches. Among techniques, lr-CLAL may offer advantages over KLAL due to lower rejection rates. Despite encouraging results, long-term data remain limited for newer approaches such as allo-CLET and allo-SLET. Careful postoperative monitoring and management of complications, including rejection, glaucoma, and microbial keratitis, remain essential to optimize outcomes.

异体眼表干细胞移植的疗效。
同种异体眼表面干细胞移植(OSST)是一种成熟的治疗角膜缘干细胞缺乏症的方法,其应用的技术包括角膜缘同种异体移植(KLAL)、活体结膜角膜缘同种异体移植(lr-CLAL)、同种异体培养角膜缘上皮移植(alloo - clet)和同种异体单纯角膜缘上皮移植(alloo - slet)。本综述综合了35项研究的证据,涉及1268只眼睛,随访至少24个月,以评估中期和长期结果。总的来说,OSST与视力的改善和眼表稳定性的恢复有关,尽管成功率因技术而异,从13%到87%不等。结果似乎受到全身免疫抑制强度的影响,与单药或双药方法相比,三联药方案显示出更高的长期成功率。在各种技术中,由于拒绝率较低,lr-CLAL可能比KLAL具有优势。尽管取得了令人鼓舞的结果,但对于诸如allow - clet和allow - slet之类的新方法,长期数据仍然有限。仔细的术后监测和并发症管理,包括排斥反应、青光眼和微生物角膜炎,仍然是优化结果的必要条件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书